Status:
COMPLETED
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Lead Sponsor:
Novartis Vaccines
Conditions:
Meningococcal Infections
Meningococcal Meningitis
Eligibility:
All Genders
11-55 years
Phase:
PHASE3
Brief Summary
This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.
Eligibility Criteria
Inclusion
- Healthy subjects who are 11-55 years of age inclusive and who have given appropriate written assent and/or consent
Exclusion
- Subjects with a previous or suspected disease caused by N. meningitidis
- previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)
- previous or suspected disease caused by N. meningitidis
- Any serious acute, chronic or progressive disease
- Pregnant or breastfeeding
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
3539 Patients enrolled
Trial Details
Trial ID
NCT00450437
Start Date
March 1 2007
End Date
January 1 2008
Last Update
January 28 2015
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35205, 35244
2
Tuscaloosa, Alabama, United States, 35487
3
Fremont, California, United States, 94538
4
Fresno, California, United States, 93726